This supports the approach of selective VEGFR-3 pathway inhibition to achieve antitumor effects by cooperative modulation of lymphatic and blood vessels in the tumor, which suppresses VEGFR-3–mediated immune tolerance and prevents macrophage polarization into immunosuppressive cells (28). The gene discussed is FLT4; the disease is neoplasm.